EYP-1901 demonstrates potential for neovascular age-related macular degeneration
A phase 2 study found that EYP-1901 with supplemental aflibercept as needed was non-inferior to aflibercept alone, pointing to a potential new treatment option that could reduce the frequency of dosing for patients with neovascular age-related macular degeneration (nAMD). The study was presented at the 2024 ARVO Annual Meeting in Seattle, Washington.
EYP-1901 is a sustained-delivery treatment that supplies the pan–vascular endothelial growth factor receptor inhibitor vorolanib in a bio-erodible form. In animal studies, EYP-1901 offered consistent delivery for approximately 9 months post-injection.
The multicenter, prospective, randomized, double-masked, parallel DAVIO 2 study included patients who were previously treated for nAMD; 161 eyes were treated with:
- EYP-1901 2,060 μg (n=53)
- EYP-1901 3,090 μg (n=54)
- Aflibercept 2 mg every 8 weeks (standard of care; n=54)
EYP-1901 was administered as a single dose on week 8. Patients receiving EYP-1901 could receive supplemental aflibercept injections if their disease worsened in certain ways, as outlined by the study protocol.
The mean average change in best corrected visual acuity with EYP-1901 versus standard of care was –0.3 letters for EYP-1901 2,060 μg and –0.4 letters for EYP-1901 3,090 μg. Treatment burden was reduced by 89% and 85%, respectively. For eyes treated with EYP-1901 2,060 μg and 3,090 μg, 65% and 64%, respectively, did not require supplemental treatment for 6 months.
The adverse event profile was similar between treatment options.
“If further studies show that EYP-1901 is safe and effective, it might be possible for patients with nAMD to get injections every 6 months or less often instead of every 1 [to] 3 months,” the authors concluded.
Reference
Eichenbaum DA, Hershberger V, Patel SS, et al. The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration. Abstract 4401-A0120. Presented at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting, May 5-9, Seattle, Washington.
